Related references
Note: Only part of the references are listed.Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy
Y. L. B. Klaver et al.
ANNALS OF ONCOLOGY (2011)
Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study
Valery E. Lemmens et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX
Markus Klinger et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Peritoneal VEGF burden as a predictor of cytoreductive surgery outcome in women with epithelial ovarian cancer
Solange Maria Diniz Bizzo et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2010)
A Systematic Review and Meta-Analysis of Cytoreductive Surgery with Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin
Christopher Cao et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Imaging of Peritoneal Carcinomatosis
Santiago Gonzalez-Moreno et al.
CANCER JOURNAL (2009)
Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia With Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin
Dominique Elias et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon
Jocelyn M. Logan-Collins et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement
J. Esquivel et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma
Tristan D. Yan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer:: European Organisation for Research and Treatment of Cancer Gastrointestinal Group study 40986
CH Köhne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Addition of bevacizurnab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial
FF Kabbinavar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bevacizurnab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer
HI Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer
VJ Verwaal et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Peritoneal carcinomatosis from colorectal cancer
DG Jayne et al.
BRITISH JOURNAL OF SURGERY (2002)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
LB Saltz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard et al.
LANCET (2000)
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
S Giacchetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)